Skip to content
Peptide research

Ecnoglutide

Also known as XW003
Category
Weight Management & Metabolic
Administration routes
Injectable
Regulatory status
Not FDA-approved

A cAMP-biased GLP-1 receptor agonist marketed for weight loss and glucose control in type 2 diabetes. Human data are unusually strong for a peptide, roughly 15% weight loss at 48 weeks plus A1c and liver fat gains, but nearly all from Chinese trials, unconfirmed elsewhere. Risks include GLP-1 nausea, an unresolved theoretical thyroid tumor signal, and a new mechanism with no long-term safety record. Not an approved drug in the US; supply warrants caution.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Ecnoglutide is the world's first approved cAMP-biased GLP-1 receptor agonist, developed by Hangzhou Sciwind Biosciences (China). It was approved by China's National Medical Products Administration (NMPA) in March 2026 for chronic weight management in adults with overweight or obesity. Unlike conventional GLP-1 agonists like semaglutide that activate both cAMP and beta-arrestin signaling pathways, ecnoglutide selectively activates the cAMP pathway while minimizing beta-arrestin recruitment, which is believed to deliver more potent and sustained weight loss with a potentially differentiated side effect profile.

In the Phase 3 SLIMMER trial in Chinese adults with overweight or obesity, ecnoglutide at the highest dose achieved a mean 15.4% reduction in body weight from baseline (15.1% placebo-adjusted) at 48 weeks. 92.8% of patients achieved clinically meaningful weight loss of at least 5% — nearly seven times the placebo response rate. Furthermore, 79.6% achieved at least 10% weight loss and 63.5% achieved at least 15% weight loss, with no plateau observed at 48 weeks.

Ecnoglutide has also been studied for type 2 diabetes in the Phase 3 EECOH-1 trial (n=211), where the higher dose achieved a 2.43% reduction in HbA1c from baseline (1.56% placebo-adjusted) at 24 weeks. The drug additionally showed significant improvements in cardiometabolic risk factors, liver fat content, and uric acid levels. While currently approved only in China, ecnoglutide's results have been published in The Lancet Diabetes & Endocrinology and Nature Communications, and highlighted in Nature.

How it works in the body

A cAMP-biased GLP-1 receptor agonist, meaning it preferentially activates the cAMP signaling pathway over beta-arrestin recruitment. This biased signaling profile may reduce GI side effects while maintaining full metabolic efficacy for appetite suppression and glycemic control.

Research overview

Ecnoglutide was developed by Sciwind Biosciences based on the cAMP-biased GLP-1 receptor agonism mechanism. Phase 2 data in T2D (China Drug Trials Registry CTR20211014, n=145) were published in Nature Communications (2024) showing dose-dependent HbA1c reductions. The Phase 3 SLIMMER trial for obesity (NCT05813795, published in The Lancet Diabetes & Endocrinology, June 2025) enrolled Chinese adults with overweight/obesity and demonstrated 15.4% mean weight loss at 2.4 mg at 48 weeks. The Phase 3 EECOH-1 trial for T2D (NCT05680155, n=211, published in Nature Communications in January 2026) enrolled adults from 32 medical centers in China, randomized 2:2:1:1 to ecnoglutide 0.6 mg, 1.2 mg, or volume-matched placebo for 24 weeks. HbA1c reductions were -1.96% (0.6 mg) and -2.43% (1.2 mg) vs -0.87% (placebo). Weight loss of up to 6.5 kg was observed at 1.2 mg. Ecnoglutide was approved by NMPA (China's FDA) in March 2026. Clinical results have been presented at ADA Scientific Sessions and EASD Annual Meeting. Ecnoglutide also showed 53.1% liver fat reduction in patients with elevated baseline liver fat, and uric acid reduction up to 54.3 micromol/L.

Who researches Ecnoglutide?

Commonly researched by

  • People researching weight management options

    Studied for effects on body composition, appetite regulation, or metabolic rate.

  • People researching blood sugar regulation

    Studied for effects on insulin sensitivity, glucose metabolism, or glycemic control.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(4)

Rated by level of concern

  • Gastrointestinal adverse events (GLP-1 class effects)

    High

    PMID 40555243 (Lancet Diabetes Endocrinol 2025)

  • Limited data outside Chinese populations

    High

    PMID 40555243; PMID 41501026; PMID 40854315; PMID 42412371

  • Thyroid C-cell tumor risk (GLP-1 class warning)

    Theoretical

    FDA labelling for the GLP-1 RA class (e.g. Ozempic/Wegovy boxed warning); no ecnoglutide-specific human data

  • Novel biased mechanism with limited long-term safety data

    Moderate

    PMID 40555243; PMID 40854315; NMPA approvals Jan/Mar 2026 (PMID 42412371)

Interaction summary(9)

Rated by direction with this peptide

  • Insulin

    CautionHigh

    Adding a GLP-1 RA to insulin substantially raises hypoglycaemia risk; insulin dose reduction and glucose monitoring are standard class practice, and this applies to ecnoglutide's approved T2D indication. Class-level, not ecnoglutide-specific (its pivotal T2D trials were monotherapy or metformin-background).

    GLP-1 RA class labelling (FDA semaglutide/Ozempic, Warnings and Drug Interactions); ADA Standards of Care

  • Sulfonylureas (glimepiride, gliclazide) and glinides

    CautionHigh

    Insulin secretagogues combined with a GLP-1 RA markedly increase hypoglycaemia risk; pre-emptive sulfonylurea dose reduction is the class recommendation. Class-level inference for ecnoglutide.

    GLP-1 RA class labelling (FDA); ADA Standards of Care

  • Other GLP-1 receptor agonists / incretin agents (semaglutide, tirzepatide, liraglutide)

    CautionModerate

    This is duplicative pharmacology with additive GI burden and no evidence of added benefit, not a documented high-severity interaction. Ecnoglutide should replace, not be used alongside, another GLP-1 RA; no combination trials exist.

    Class pharmacology and guideline practice; no combination trials exist

  • Narrow-therapeutic-index oral drugs (warfarin, levothyroxine, antiepileptics, digoxin)

    CautionModerate

    GLP-1 RAs delay gastric emptying and can alter the rate (and occasionally extent) of oral absorption, so INR/TSH/drug-level monitoring is reasonable during dose escalation. This is a class mechanism; dedicated PK studies with injectable GLP-1 RAs have generally shown no clinically meaningful change, and no ecnoglutide DDI study has been published.

    GLP-1 RA class labelling (delayed gastric emptying, Drug Interactions section); no published ecnoglutide DDI study

  • Anesthesia and procedural sedation (endoscopy, surgery)

    CautionModerate

    Delayed gastric emptying can leave retained gastric contents despite standard fasting, raising aspiration risk. Guidance has evolved: 2023 ASA consensus suggested holding weekly GLP-1 RAs before elective procedures, while the 2024 multisociety guidance moved away from routine discontinuation toward individualised risk assessment (clear-liquid diet the day before, gastric ultrasound where available).

    ASA 2023 consensus guidance; 2024 multisociety clinical practice guidance on periprocedural GLP-1 RA management

  • DPP-4 inhibitors (sitagliptin, linagliptin)

    CautionLow

    Mechanistically redundant - both act on the incretin axis - so combination adds cost without expected additive glycaemic benefit; guidelines advise against pairing them. Redundancy, not toxicity.

    ADA Standards of Care; incretin class pharmacology

  • Metformin

    SynergisticLow

    Complementary glucose-lowering mechanisms with no clinically significant interaction expected. Metformin background therapy was used in the ecnoglutide T2D programme (phase 2 and the EECOH-2 comparator trial); no formal interaction study was performed.

    PMID 40854315 (EECOH-2); Nat Commun 2024 s41467-024-52353-y (phase 2)

  • SGLT2 inhibitors (empagliflozin, dapagliflozin)

    SynergisticLow

    Independent mechanisms give additive weight and glycaemic effects with low hypoglycaemia risk. Extrapolated from GLP-1 class combination evidence; not tested with ecnoglutide.

    ADA Standards of Care; class-level combination evidence (no ecnoglutide-specific data)

  • Alcohol

    CautionLow

    Alcohol compounds hypoglycaemia risk when ecnoglutide is combined with insulin or a sulfonylurea and can worsen nausea; no ecnoglutide-specific data.

    General GLP-1 RA / antihyperglycaemic clinical guidance

Known risks(4)

  • Gastrointestinal adverse events (GLP-1 class effects)

    Mild to Moderate

    Nausea, diarrhea, and vomiting are expected GLP-1 class effects. Biased agonism may modulate but does not eliminate these events.

  • Limited data outside Chinese populations

    All Phase 3 data are from Chinese adults. Efficacy and safety in other ethnic populations have not been established. Metabolic responses may differ across populations.

  • Thyroid C-cell tumor risk (GLP-1 class warning)

    Theoretical / Precautionary

    All GLP-1 receptor agonists carry a precaution based on rodent thyroid C-cell tumors. Not confirmed in humans.

  • Novel biased mechanism with limited long-term safety data

    The cAMP-biased mechanism is first-in-class. While initial data are encouraging, long-term consequences of selective pathway activation are not fully characterized. Post-marketing surveillance will be important.

Drug interactions(4)

  • Insulin and insulin secretagogues (sulfonylureas, meglitinides)

    Increased risk of hypoglycemia due to GLP-1-mediated enhancement of insulin secretion. Dose adjustments may be needed.

  • Other GLP-1 receptor agonists

    Co-administration not recommended due to overlapping mechanisms and risk of additive GI side effects.

  • Oral medications with narrow therapeutic index

    GLP-1 agonists delay gastric emptying, potentially altering absorption of co-administered oral drugs.

  • Oral contraceptives

    Delayed gastric emptying may reduce absorption of oral contraceptives. Backup contraception advised during dose escalation.

Research & benefits

Evidence base

Evidence Level
Strong Evidence (Phase 3, Approved in China)
Total Studies
10
Human Studies
At least 1,020 randomized participants across the three listed trials, including placebo groups; this is not a complete development-program total.

Ecnoglutide has completed Phase 3 trials for both obesity (SLIMMER) and type 2 diabetes (EECOH-1) with results published in top-tier journals (The Lancet Diabetes & Endocrinology, Nature Communications). It has been approved by China's NMPA for chronic weight management. Phase 3 data demonstrated 15.4% weight loss at 48 weeks and 2.43% HbA1c reduction at 24 weeks. All trials were conducted in Chinese populations; global Phase 3 data are not yet available.

Researched for(6)

Rated by confidence in the evidence

  • Exceptional weight loss (15.4% at 48 weeks, no plateau observed)

    High

    Peer-reviewed phase 3 RCT showed 13.2% loss at 40 weeks; 48-week 15.4% figure is company-reported.

    PMID 40555243 (Lancet Diabetes Endocrinol, Sep 2025); 48-week/15.4% figure: Sciwind NMPA approval release, 6 Mar 2026 (prnewswire 302706442)

  • 92.8% of patients achieved clinically meaningful >=5% weight loss

    High

    Randomized trial confirmed high response rates; the 92.8% figure comes from company reporting.

    PMID 40555243 (week-40 responder rates); 92.8% figure: Sciwind NMPA approval release, 6 Mar 2026 (prnewswire 302706442)

  • Superior HbA1c reduction in T2D (up to 2.43% from baseline at 1.2 mg)

    High

    Two randomized phase 3 trials showed greater HbA1c reduction than placebo and dulaglutide.

    PMID 41501026 (EECOH-1, Nat Commun 2026); PMID 40854315 (EECOH-2, Lancet Diabetes Endocrinol 2025); phase 2 support: Nat Commun 2024 s41467-024-52353-y

  • Significant liver fat reduction (53.1% in patients with elevated baseline liver fat)

    Medium

    Reported only in a company release as a subgroup finding, not in peer-reviewed data.

    Sciwind NMPA approval release, 6 Mar 2026 (prnewswire 302706442)

  • Comprehensive cardiometabolic improvements (waist circumference, BP, lipids, uric acid)

    Medium

    Secondary trial measures reported only in a company release, without effect sizes or comparisons.

    Sciwind NMPA approval release, 6 Mar 2026; trial context: PMID 40555243

  • First approved biased-mechanism GLP-1 — potentially more efficient receptor activation

    Speculative

    Approval is confirmed; efficiency or tolerability benefit from signaling bias remains unproven so far.

    PMID 42412371 (Drugs 2026, First Approvals); mechanism: Mol Metab 2023 (Guo W et al.); comparator data: PMID 40854315

Benefits(6)

  • Exceptional weight loss (15.4% at 48 weeks, no plateau observed)

    Phase 3 SLIMMER trial (Lancet Diabetes Endocrinol 2025, Chinese adults with obesity)

  • 92.8% of patients achieved clinically meaningful >=5% weight loss

    Phase 3 SLIMMER trial — nearly 7x the placebo response rate

  • Superior HbA1c reduction in T2D (up to 2.43% from baseline at 1.2 mg)

    Phase 3 EECOH-1 (NCT05680155, n=211, Nature Communications 2025)

  • Significant liver fat reduction (53.1% in patients with elevated baseline liver fat)

    Phase 3 SLIMMER — ecnoglutide 2.4 mg group

  • Comprehensive cardiometabolic improvements (waist circumference, BP, lipids, uric acid)

    SLIMMER trial — uric acid reduction up to 54.3 micromol/L, improved lipid panel

  • First approved biased-mechanism GLP-1 — potentially more efficient receptor activation

    Sciwind preclinical and clinical program — biased agonism selectively activates cAMP

Key studies(3)

  1. Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide for weight management (SLIMMER Phase 3)

    Phase 3 RCTn=664 randomized Chinese adults with overweight or obesity48 weeks

    Sciwind Biosciences / Ji L (PI)

    The Lancet Diabetes & Endocrinology

    2025

    Ecnoglutide 2.4 mg weekly achieved 15.4% mean weight loss (15.1% placebo-adjusted). 92.8% achieved >=5% weight loss, 79.6% achieved >=10%, 63.5% achieved >=15%. No plateau at 48 weeks. Significant cardiometabolic improvements and 53.1% liver fat reduction.

  2. Sciwind Biosciences investigators

    Nature Communications

    2026

    Ecnoglutide 0.6 mg achieved HbA1c -1.96% and 1.2 mg achieved -2.43% vs -0.87% placebo. Estimated treatment differences: -1.09% (0.6 mg, p=0.0003) and -1.56% (1.2 mg, p<0.0001). Ecnoglutide represents a potential monotherapy option for T2DM.

  3. Sciwind Biosciences investigators

    Nature Communications

    2024

    Dose-dependent HbA1c reductions in adults with T2DM. Results supported dose selection for Phase 3 EECOH-1 trial.

Regulation & availability

Why researchers look at it

Ecnoglutide is the first biased-mechanism GLP-1 agonist to reach the market, achieving 15.4% weight loss at 48 weeks with no plateau and an astonishing 93% clinically meaningful response rate. Its selective cAMP pathway activation represents a genuinely new approach to GLP-1 pharmacology that may unlock better efficacy and tolerability profiles.

Estimated cost
Available in China (~¥3,000-5,000/mo); not available elsewhere (Sciwind Biosciences)
FDA status
Ecnoglutide is an investigational drug. It is not FDA-approved, and in the US it is available only through clinical trials; it is not eligible for compounding. In China, approval for adult type 2 diabetes was announced in January 2026, followed by weight management in March 2026. The cited Phase 3 studies enrolled Chinese populations.
WADA status
Not Explicitly Listed on the 2026 WADA Prohibited List. GLP-1 receptor agonists as a class are not currently prohibited by WADA, though semaglutide and tirzepatide are under the 2026 Monitoring Program. Ecnoglutide, being newly approved in China only, is not yet specifically addressed.
Prescribability
Ecnoglutide is an investigational drug. It is not FDA-approved, and in the US it is available only through clinical trials; it is not eligible for compounding. Yes in China — adult type 2 diabetes approval announced January 2026; weight-management approval announced March 2026.
Availability
Ecnoglutide has Chinese approvals for adult type 2 diabetes and chronic weight management, announced in January and March 2026, respectively. Sciwind identifies Pfizer as its mainland-China commercialization partner. No US or EU approval was identified as of October 14, 2026; local supply requires confirmation.

International status

  • US

    Not approved; no US trials announced

  • China

    Approved: adult type 2 diabetes, announced January 2026; chronic weight management, announced March 2026. Developer: Sciwind Biosciences.

  • Worldwide

    Approved only in China

Regulatory timeline(7)

  1. 2022-12
    EECOH-1 Phase 3 trial (T2D) initiated in China (NCT05680155)
  2. 2023
    SLIMMER Phase 3 trial (obesity) initiated in Chinese adults (NCT05813795)
  3. 2024-09
    Phase 2 T2D results published in Nature Communications
  4. 2025-06
    SLIMMER Phase 3 results published in Lancet Diabetes & Endocrinology; highlighted in Nature
  5. 2026-01-07
    EECOH-1 results published in Nature Communications.
  6. 2025
    Clinical results presented at ADA Scientific Sessions and EASD Annual Meeting
  7. 2026-03-06
    NMPA (China) approves ecnoglutide injection for chronic weight management

Sources & FAQs

Research sources(5)

Frequently asked questions(4)

What does 'cAMP-biased' mean for ecnoglutide?

Conventional GLP-1 agonists activate two intracellular signaling pathways: cAMP (which drives metabolic benefits) and beta-arrestin (which may contribute to desensitization and some side effects). Ecnoglutide is 'biased' toward cAMP, selectively activating the beneficial pathway while minimizing beta-arrestin recruitment, potentially delivering more potent and sustained effects.

Is ecnoglutide available in the US?

No. Ecnoglutide is approved only in China (NMPA, March 2026). It has not been submitted to the FDA or EMA, and no global regulatory timeline has been announced. All Phase 3 data are from Chinese populations.

How does ecnoglutide compare to semaglutide for weight loss?

In the SLIMMER trial, ecnoglutide achieved 15.4% weight loss at 48 weeks in Chinese adults — numerically comparable to or exceeding semaglutide (Wegovy) results in similar populations. An open-label randomized Phase 2 comparison with semaglutide has been conducted. Sciwind presented interim week-20 results in June 2026; these are not final trial results.

What are the side effects of ecnoglutide?

The most common side effects are gastrointestinal (nausea, diarrhea, vomiting), consistent with the GLP-1 agonist class. In Phase 3 trials, the biased mechanism did not eliminate GI side effects but may improve the overall tolerability profile over time.